

100
112
106
120
116
102
130
132
108
B
B
104
114
110

FIG. 1A



106
108
122
102
124
114
112
104
110

FIG. 1B




FIG. 2A




FIG. 2B




FIG. 3B




FIG. 3A




FIG. 3C




FIG. 4A




FIG. 4B




FIG. 5A




FIG. 5B




FIG. 6



GEMCITABINE CONC. IN PROSTATE POST BLADDER PERFUSION
14C GEMCITABINE CONC (ng/g)
2000.00
1500.00
1000.00
500.00
0.00
24HR IV SINGLE DOSE
6HR BLADDER PERF
24HR BLADDER PERF
IN-VITRO PROSTATE POTENCY RANGE
HIGH RANGE IN-VITRO IC50 (200 ng/ml)
LOW RANGE IN-VITRO IC50 (10 ng/ml)

FIG. 7



GEMCITABINE PLASMA LEVEL
GEMCITABINE PLASMA LEVEL (ug-eq/ml)
COLLECTION TIME (HR)
0
5
10
15
20
25
30
A1-6HR
A2-6HR
A3-6HR
A4-24H
A5-24HR
A6-24HR
A7-IV
A8-IV
A9-IV

FIG. 8



14C GEMCITABINE BLADDER CONCENTRATION
14C GEMCITABINE CONC (ug/g)
25.0
20.0
15.0
10.0
5.0
0.0
HIGH RANGE IN-VITRO IC50
(3 ug/ml)
LOW RANGE IN-VITRO IC50
(1 ug/ml)
2HR
24H
2HR
6HR
24HR
IV SINGLE DOSE*
BLADDER PERFUSION

FIG. 9




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 11



GEMCITABLINE RELEASE RATE (mg FBE/DAY)
60
50
40
30
20
10
0
R204-4 TO 6
0
1
2
3
4
5
6
7
8
9
ELAPSED TIME (DAYS)

FIG. 12



GEMCITABINE AND dFdU URINE CONCENTRATION (μg/mL)
30
25
20
15
10
5
0
ANIMAL 1
ANIMAL 2
ANIMAL 3
0
1
2
3
4
5
6
7
8
9
TIME (DAYS)

FIG. 13



EXPECTED
OBSERVED
TARGET* EFFECTIVE RANGE
[GEMCITABINE] (μg/g TISSUE)
20
18
16
14
12
10
8
6
4
2
0
EPITHELIUM
LAMINA PROPRIA
MUSCULARIS
ADVENTITIA

FIG. 14